Bernard Cribier

Bernard Cribier

Auto-generated profile, based on publicly available information

Bernard Cribier

Dermatologie et dermatopathologie, hôpitaux universitaires, université de Strasbourg, Strasbourg, France

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2011 in The American Journal of Dermatopathology
Verified
Journal Article
Closed access
JCJ Andrew Md Carlson
J Andrew Md Carlson
GDGanary Dabiri
Ganary Dabiri
BCBernard Cribier
Bernard Cribier
SSStewart Sell
Stewart Sell
Syphilis has plagued mankind for centuries and is currently resurgent in the Western hemisphere. Although there has been a significant reduction of tertiary disease and recognition of facilitative interactions with human immunodeficiency virus infection, the natural history of syphilis has remained largely unchanged; thus, new strategies are required to more effectively combat this pathogen. The immunopathologic features of experimental syphilis in the rabbit; the course, stages, and pathology of human syphilis; and a comparison of human syphilis with leprosy suggest that the clinical course of syphilis and its tissue manifestations are determined by the balance between delayed-type hypersensitivity (DTH) and humoral immunity to the causative agent, Treponema pallidum. A strong DTH response is associated with clearance of the infecting organisms in a well-developed chancre, whereas a cytotoxic T-cell response or strong humoral antibody response is associated with prolonged infection and progression to tertiary disease. Many of the protean symptoms/appearances of secondary and tertiary human syphilis are manifestations of immune reactions that fail to clear the organism, due to a lack of recruitment and, more importantly, activation of macrophages by sensitized CD4 T cells. The Bacillus Calmette-Guerin vaccination can enhance DTH and has been shown to produce a low, but measurable, beneficial effect in the prevention of leprosy, a disease that shows a disease spectrum with characteristics in common with syphilis. In the prevention of syphilis, a potential vaccine protective against syphilis should be designed to augment the DTH response.

1 December 2001 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
BCBernard Cribier
Bernard Cribier
NDNadia Djeridi
Nadia Djeridi
BPBernard Peltre
Bernard Peltre
EGEdouard Grosshans
Edouard Grosshans

4 March 2013 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
PDF file
BCB. Cribier
B. Cribier

18 January 2022 in Cancers
Verified
Journal Article
Open access
PDF file
NMNicolas Macagno
Nicolas Macagno
PSPierre Sohier
Pierre Sohier
TKThibault Kervarrec
Thibault Kervarrec
DPDaniel Pissaloux
Daniel Pissaloux
MJMarie-Laure Jullie
Marie-Laure Jullie
Maxime BattistellaMaxime Battistella
Maxime Battistella
Cutaneous sweat gland tumors are a subset of adnexal neoplasms that derive or differentiate into the sweat apparatus. Their great diversity, rarity, and complex terminology make their pathological diagnosis challenging. Recent findings have revealed a wide spectrum of oncogenic drivers, several of which are of diagnostic interest for pathologists. Most of these molecular alterations are represented by gene fusions, which are shared with other homologous neoplasms occurring in organs containing exocrine glands, such as salivary and breast glands, which show similarities to the sweat apparatus. This review aims to provide a synthesis of the most recent immunohistochemical and molecular markers used for the diagnosis of sweat gland tumors and to highlight their relationship with similar tumors in other organs. It will cover adenoid cystic carcinoma (NFIB, MYB, and MYBL1 fusion), cutaneous mixed tumor (PLAG1 fusion), cylindroma and spiradenoma and their carcinomas thereof (NF-κB activation through CYLD inactivation or ALKP1 hotspot mutation), hidradenoma and hidradenocarcinoma (MAML2 fusion), myoepithelioma (EWSR1 and FUS fusion), poroma and porocarcinoma (YAP1, MAML2, and NUTM1 fusion), secretory carcinoma (ETV6, NTRK3 fusion), tubular adenoma and syringo-cystadenoma papilliferum (HRAS and BRAF activating mutations). Sweat gland tumors for which there are no known molecular abnormalities will also be briefly discussed, as well as potential future developments.

1 May 2020 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
TKThibault Kervarrec
Thibault Kervarrec
MAMohanad Aljundi
Mohanad Aljundi
SASilke Appenzeller
Silke Appenzeller
MSMahtab Samimi
Mahtab Samimi
EMEve Maubec
Eve Maubec
RHRoland Houben
Roland Houben

1 November 2011 in Annales de Dermatologie et de Vénéréologie
Verified
Journal Article
Closed access
BCB. Cribier
B. Cribier